Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Antares Pharma management to meet virtually with Piper Sandler » 04:55
05/17/21
05/17
04:55
05/17/21
04:55
ATRS

Antares Pharma

$4.00 /

+0.195 (+5.12%)

Virtual Meeting to be…

Virtual Meeting to be held on May 17 hosted by Piper Sandler.

ShowHide Related Items >><<
ATRS Antares Pharma
$4.00 /

+0.195 (+5.12%)

ATRS Antares Pharma
$4.00 /

+0.195 (+5.12%)

Conference/Events
Antares Pharma management to meet virtually with Piper Sandler » 10:50
05/14/21
05/14
10:50
05/14/21
10:50
ATRS

Antares Pharma

$3.88 /

+0.075 (+1.97%)

Virtual Meeting to be…

Virtual Meeting to be held on May 17 hosted by Piper Sandler.

ShowHide Related Items >><<
ATRS Antares Pharma
$3.88 /

+0.075 (+1.97%)

ATRS Antares Pharma
$3.88 /

+0.075 (+1.97%)

Hot Stocks
Antares Pharma appoints Joseph Renda as SVP, commercial » 08:11
05/06/21
05/06
08:11
05/06/21
08:11
ATRS

Antares Pharma

$3.78 /

+0.04 (+1.07%)

Antares Pharma announced…

Antares Pharma announced the appointment of Joseph Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals.

ShowHide Related Items >><<
ATRS Antares Pharma
$3.78 /

+0.04 (+1.07%)

ATRS Antares Pharma
$3.78 /

+0.04 (+1.07%)

Earnings
Antares Pharma reaffirms 2021 revenue view of $175M-$200M, consensus $187.23M » 07:39
05/06/21
05/06
07:39
05/06/21
07:39
ATRS

Antares Pharma

$3.78 /

+0.04 (+1.07%)

, TEVA

Teva

$10.36 /

+0.26 (+2.58%)

Antares Pharma (ATRS)…

Antares Pharma (ATRS) reaffirmed FY21 revenue guidance in the range of $175M-$200M, which represents a 17%-34% year-over-year growth rate and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic and a range of revenue scenarios for the potential approval and launch of generic Forteo by partner Teva (TEVA) in the U.S.

ShowHide Related Items >><<
TEVA Teva
$10.36 /

+0.26 (+2.58%)

ATRS Antares Pharma
$3.78 /

+0.04 (+1.07%)

ATRS Antares Pharma
$3.78 /

+0.04 (+1.07%)

TEVA Teva
$10.36 /

+0.26 (+2.58%)

05/04/21 UBS
Teva downgraded to Neutral from Buy at UBS
04/06/21 RBC Capital
Teva transferred with a Sector Perform at RBC Capital
01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
12/21/20 Gabelli
Teva named 'Best Idea for 2021' at Gabelli
TEVA Teva
$10.36 /

+0.26 (+2.58%)

ATRS Antares Pharma
$3.78 /

+0.04 (+1.07%)

TEVA Teva
$10.36 /

+0.26 (+2.58%)

TEVA Teva
$10.36 /

+0.26 (+2.58%)

TEVA Teva
$10.36 /

+0.26 (+2.58%)

Earnings
Antares Pharma reports Q1 EPS 2c, consensus 1c » 07:33
05/06/21
05/06
07:33
05/06/21
07:33
ATRS

Antares Pharma

$3.78 /

+0.04 (+1.07%)

Reports Q1 revenue…

Reports Q1 revenue $42.083M consensus $38.47M. Robert Apple, President and CEO of Antares Pharma, commented, "Our strong first quarter results with a 27% year-over-year revenue increase continue to highlight the growth opportunities and initiatives we have across our diversified business. With XYOSTED total prescription growth of 50% year-over-year, we expect to continue to build positive momentum throughout the year as patient visits to physician offices increase and our sales representatives garner more in-office physician details, and as vaccines are administered and the pandemic slows. Furthermore, our commercial organization implemented an enhanced targeting strategy that reinforces the expansion opportunities for XYOSTED and the relaunch of NOCDURNA. We are also very pleased with the 48% year-over-year increase in prescriptions from our partner Teva's generic EpiPen and look forward to the potential approval of their generic teriparatide in the U.S. Overall, as we concurrently advance our robust development pipeline with an expanded leadership team, we believe we have a diverse product portfolio that will support our full year 2021 revenue guidance as well as future growth."

ShowHide Related Items >><<
ATRS Antares Pharma
$3.78 /

+0.04 (+1.07%)

ATRS Antares Pharma
$3.78 /

+0.04 (+1.07%)

Hot Stocks
Antares Pharma announces poster presentation at Pediatric Endocrine Society 2021 » 09:02
05/03/21
05/03
09:02
05/03/21
09:02
ATRS

Antares Pharma

$3.80 /

-0.07 (-1.81%)

Antares Pharma announced…

Antares Pharma announced that data highlighting the therapeutic potential of subcutaneous testosterone enanthate in younger hypogonadal populations was presented in a poster presentation at the Pediatric Endocrine Society 2021 Virtual Annual Meeting on April 30 - May 3. The poster presentation entitled, "Allometric Scaling of Testosterone Enanthate Pharmacokinetics from Adult Males to Adolescent Hypogonadal Males After IM and SC Administration Using Population PK Modeling", was presented by Maria Vogiatzi, MD, Professor of Pediatrics and Director, Adrenal and Puberty Center, Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Pharmacokinetic modelling of datasets from the company's Phase 2 trial for XYOSTED for the treatment of hypogonadism in adult males was performed to permit the extrapolation of testosterone exposure to patients with body weights typical of preadolescent males. The PK modelling showed that subcutaneous testosterone enanthate dosed at a reduced frequency predicted testosterone exposure similar to normal adolescents and could represent a viable treatment option for permanently hypogonadal adolescent males, who require lifelong hormonal support.

ShowHide Related Items >><<
ATRS Antares Pharma
$3.80 /

-0.07 (-1.81%)

ATRS Antares Pharma
$3.80 /

-0.07 (-1.81%)

Hot Stocks
Antares Pharma appoints Richardson as executive Vice President, CMO » 08:37
04/26/21
04/26
08:37
04/26/21
08:37
ATRS

Antares Pharma

$3.98 /

+0.04 (+1.02%)

Antares Pharma announced…

Antares Pharma announced the appointment of Peter Richardson, MRCP, as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the company's proprietary research and development programs, including ideation, formulation, clinical operations, pharmacovigilance and medical affairs. Dr. Richardson has over 25 years of research and development experience. From 2016 until the acquisition of the company in 2020, Richardson was Chief Medical Officer for Adare Pharmaceuticals and Vice President of Research and Development and President, Adare Pharmaceuticals US.

ShowHide Related Items >><<
ATRS Antares Pharma
$3.98 /

+0.04 (+1.02%)

ATRS Antares Pharma
$3.98 /

+0.04 (+1.02%)

Over a quarter ago
Earnings
Antares Pharma reaffirms 2021 revenue view $175M-$200M, consensus $184.88M » 07:11
03/02/21
03/02
07:11
03/02/21
07:11
ATRS

Antares Pharma

$4.50 /

+0.225 (+5.26%)

The Company today…

The Company today reaffirmed full-year 2021 revenue guidance in the range of $175-200 million, which represents a 17% to 34% year-over-year growth rate and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic and a range of revenue scenarios for the potential approval and launch of generic Forteo by our partner Teva in the U.S.

ShowHide Related Items >><<
ATRS Antares Pharma
$4.50 /

+0.225 (+5.26%)

ATRS Antares Pharma
$4.50 /

+0.225 (+5.26%)

Earnings
Antares Pharma reports Q4 EPS 30c, consensus 3c » 07:10
03/02/21
03/02
07:10
03/02/21
07:10
ATRS

Antares Pharma

$4.50 /

+0.225 (+5.26%)

Reports Q4 revenue…

Reports Q4 revenue $44.1M, consensus $40.75M. Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, "We are very proud of our accomplishments this past year that contributed to record annual revenue of $150 million. Despite ongoing challenges due to the global COVID-19 pandemic, the diversification of our business with our proprietary and partner revenue continues to bolster our overall growth, profitability, and cash flow. Driven by strong demand for XYOSTED, our proprietary revenue grew to $63 million in 2020. The reach of our commercial sales organization to urologists and endocrinologists has continued to drive the success of XYOSTED as well as support the expansion of our proprietary portfolio with NOCDURNA. We look forward to further expanding our internal pipeline as we advance our endocrinology and urology assets from successful Pre-IND meetings with the FDA last year to IND submissions this year. Our partner business also had another strong year with total revenue of $87 million driven in large part to the significant increases in market share of Teva's generic EpiPen."

ShowHide Related Items >><<
ATRS Antares Pharma
$4.50 /

+0.225 (+5.26%)

ATRS Antares Pharma
$4.50 /

+0.225 (+5.26%)

Earnings
Antares Pharma narrows 2020 revenue view $145M-$150M from $135M-$155M  08:18
01/11/21
01/11
08:18
01/11/21
08:18
ATRS

Antares Pharma

$3.97 /

+0.02 (+0.51%)

Consensus $145.6M

ShowHide Related Items >><<
ATRS Antares Pharma
$3.97 /

+0.02 (+0.51%)

ATRS Antares Pharma
$3.97 /

+0.02 (+0.51%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.